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Rare Deletions at the Neurexin 3 Locus
in Autism Spectrum Disorder
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Sarah Curran,5,6 Caroline Ogilvie,7 Joo Wook Ahn,7 Irene Drmic,8 Lili Senman,8 Christina Chrysler,9
Ann Thompson,9 Carolyn Russell,9 Aparna Prasad,1 Susan Walker,1 Dalila Pinto,1 Christian R. Marshall,1
Dimitri J. Stavropoulos,10 Lonnie Zwaigenbaum,11 Bridget A. Fernandez,12 Eric Fombonne,13
Patrick F. Bolton,5,6 David A. Collier,6 Jennelle C. Hodge,3 Wendy Roberts,8,14 Peter Szatmari,9
and Stephen W. Scherer1,2,*
The three members of the human neurexin gene family, neurexin 1 (NRXN1), neurexin 2 (NRXN2), and neurexin 3 (NRXN3), encode
neuronal adhesion proteins that have important roles in synapse development and function. In autism spectrum disorder (ASD), as
well as in other neurodevelopmental conditions, rare exonic copy-number variants and/or point mutations have been identified in
the NRXN1 and NRXN2 loci. We present clinical characterization of four index cases who have been diagnosed with ASD and who
possess rare inherited or de novo microdeletions at 14q24.3–31.1, a region that overlaps exons of the alpha and/or beta isoforms of
NRXN3. NRXN3 deletions were found in one father with subclinical autism and in a carrier mother and father without formal ASD
diagnoses, indicating issues of penetrance and expressivity at this locus. Notwithstanding these clinical complexities, this report on
ASD-affected individuals who harbor NRXN3 exonic deletions advances the understanding of the genetic etiology of autism, further
enabling molecular diagnoses.Incremental progress has been made in elucidating genetic
factors involved in autism spectrum disorder (ASD [MIM
209850]). Most notably, researchers have identified both
rare inherited and de novo copy-number variants (CNVs)
and have subsequently performed sequence-based valida-
tion.1–9 NRXN1,1 NLGN3,10 NLGN4,10 SHANK3,11,12 and
SHANK213 and genomic regions at 1q21.1,1 16p11.2,3,14
DDX53-PTCHD1,3,5,15 and others9 are all bona fide ASD
risk loci.
Rare exonic deletions within NRXN1 (MIM 600565)
at 2p16.3 are among the most consistently observed
findings from CNV investigations of ASD. After the initial
report of 300 kb hemizygous de novo lesions that
eliminated several NRXN1 exons in two female siblings
with ASD,1 several other studies have also detected dele-
tions at this locus in ASD.4–7,16–20 Exonic NRXN1 dele-
tions, which are extremely rare in controls,19 have also
been reported in cases with schizophrenia,17,21–26 intellec-
tual disability,17,19,27 bipolar disorder,28 attention deficit
hyperactivity disorder (ADHD),29 Tourette syndrome,30
and autosomal-recessive Pitt-Hopkins syndrome.31 These
reports, taken together with findings of cognitive impair-
ments, aberrant synaptic electrophysiology, and behav-1Program in Genetics and Genome Biology, The Centre for Applied Genom
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The Americioral changes in Nrxn1-knockout mice,32 provide strong
evidence for the involvement of NRXN1 in the etiology
of ASD and other neurodevelopmental disorders. There is
also a report of a truncating mutation in NRXN2 (MIM
600566) in an ASD case.33
The human neurexin gene family includes three
unlinked genes (NRXN1, NRXN2, and NRXN3 [MIM
600567]), each of which encodes alpha and beta iso-
forms.34 The neurexins are highly expressed in presynaptic
terminals and have been shown to have important roles in
synaptic cell adhesion and neurotransmitter secretion.35
Here, we describe the pedigrees (Figure 1), detailed pheno-
types (Table 1), and genotypes (Figure 2 and Tables S1, S2,
and S4–S7, available online) of ASD cases with rare dele-
tions at 14q24.3-31.1, which overlaps NRXN3.
Initially, to assess the presence of CNVs in a research
cohort of 1,158 Canadian individuals with ASD, we geno-
typed DNA with Affymetrix GeneChip SNP 6.0 (family 1
proband [F1-003] and family 2 sister [F2-004]), Illumina
Infinium 1M single SNP (F1-003 and family 2 proband,
F2-003), Illumina Omni 2.5M (family 1 sister, F1-005),
and/or Agilent Human comparative genomic hybridiza-
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Figure 1. Pedigrees of Four Unrelated
Families with Deletions at the NRXN3
Locus
Black-filled symbols represent ASD-
affected individuals, gray-filled symbols
represent broader autism phenotype
(BAP)-affected individuals, and unfilled
symbols represent apparently unaffected
individuals. Probands are marked with an
arrow. Clinical diagnosis and segregation
of the NRXN3 deletions are shown. Chil-
dren are placed left to right in birth order
from eldest to youngest. Other CNVs and
genetic variants are found in Tables S1,
S2, and S4–S7. Abbreviations are as
follows: ADHD, attention deficit hyperac-
tivity disorder; OCD, obsessive compulsive
disorder; and NA, not assessed.approved by the Hospital for Sick Children (Toronto)
research ethics board, and informed consent was obtained.
We analyzed CNVs by using published methods,5,36,37 and
we classified them as described.38 To ascertain the preva-
lence of NRXN3 CNVs, we examined the NRXN3 region
in published data from 2,026 healthy individuals from
the Children’s Hospital of Philadelphia,39 from 2,493
controls genotyped at the University of Washington40
and in microarray data that our group analyzed from
10,603 population-based controls.3,5,15,36 This latter data-
set included 1,123 controls from northern Germany,41
1,234 controls from Ottawa42 1,120 population controls
from Ontario,43 1,056 HapMap samples,44 4,783 controls
from the Wellcome Trust Case Control Consortium
(WTCCC),45 and 1,287 controls recruited by the Study of
Addiction: Genetics and Environment (SAGE) consor-
tium.46 Control individuals were predominantly of Euro-
pean ancestry, which was comparable to the ancestry of
the ASD subjects. Families 3 and 4 were found to have
NRXN3 deletions through custom Agilent 44K microarray
analyses, which were performed at the clinical genetics
laboratories at Guy’s Hospital and the Mayo Clinic, respec-
tively. DNA from family 4 was also run on a 244K oligo Agi-
lent array.
A deletion overlapping exon 1 of the NRXN3 alpha iso-
form was detected in proband F1-003 (Figure 2).
Sequencing across the breakpoints confirmed the deletion
to be 62,939 bp (chr14: 77,933,816–77,996,755; NCBI
Build 36 [hg18]). Microarray analysis of parental DNA134 The American Journal of Human Genetics 90, 133–141, January 13, 2012detected the same deletion in the
mother. Independent validation of
the array CNV calls was performed
with real-time quantitative PCR
(qPCR) based on SYBR Green I, and
two independent primer pairs each
at NRXN3 and 7q31.1 (FOXP2) served
as a negative (diploid) control.47 The
microdeletion was found in the
proband (F1-003), mother (F1-001),
and Down-syndrome-affected sister(F1-005) (Figure S1 and Tables S1–S2). All other genic
CNVs detected in the sample from proband F1-003 were
previously detected in control samples, and those that
were rare (without overlapping CNVs in the Database of
Genomic Variants) occurred within regions devoid of any
annotated genes. We also performed targeted exome rese-
quencing of F1-001, -002, -003, -004, and -005 to search
for variants in the nondeleted NRXN3 allele and to test
for other potential genic variants that might also
contribute to the ASD phenotype. The Agilent SureSelect
50 Mb human all exon capture kit was used, and the
Life/AB SOLiD4 platform was subsequently used for
sequencing (Table S3). Three potentially interesting
missense variants in ASD candidate genes,9 namely contac-
tin 3 (CNTN3 MIM [601325]), contactin-associated
protein-like 3 (CNTNAP3MIM [610517]), and E1A-binding
protein p300 (EP300 MIM [602700]), were detected and
validated with Sanger sequencing (Table S4). F1-003 had
a normal karyotype and a normal FMR-1 repeat number.
In family 1, the male proband (F1-003) was conceived
naturally by a 33-year-old mother (F1-001) and a 35-year-
old father (F1-002; Figure 1). Table 1 summarizes the clin-
ical details. The pregnancy was uncomplicated, although
the mother contracted pneumonia at 7 months of gesta-
tion. The proband was delivered by spontaneous vaginal
delivery at 38 weeks and had a nuchal cord and birth
weight of 7 lbs, 3 oz. The parents first noted his advanced
speech and memorization of detail, as well as social diffi-
culties, at 12–24 months of age. At age 9, he was identified
Table 1. Summary of Clinical Characteristics for Individuals with NRXN3 Deletions
Patient ID
and
Karyotype
NRXN3 Deletion
Coordinatesa
and Deleted Exon(s)
Clinical Details
Dx Ax Other
F1-003
(proband)
46,XY
14q24.3
(77,933,816–77,996,755)
exon 1 (alpha)
Asperger
syndrome
(ADI-R and
clinical Dx)
Age: 16 yr, 7 months; IQ: Leiter-R
IQ¼ 119 (92%); Language: OWLS:
RL ¼ 121 (92%) and EL ¼ DTC;
Adaptive Behavior: VABS-I:
ABC ¼ 75(5%), COM ¼ 96 (39%),
DLS ¼ 94 (34%), and SOC ¼ 52 (<1%)
aggression, anger, anxiety, transition
and stimulation (photo-, phono-,
and osmophobia) difficulties,
sleeplessness, depression, and headaches
F1-005
(sister)
47,XX,+21
14q24.3
(77,933,816–77,996,755)
exon 1 (alpha)
Down syndrome
(karyotype and
clinical Dx)
First Ax. Age: 11 yr, 4 months:
ADOS-2 ¼ ASD; ADI-R ¼ Non-ASD
(except behavior); did not meet clinical
criteria (by developmental pediatrician);
no ASD Dx; IQ: Leiter-R IQ ¼ 46 (<1%);
Language: OWLS: TL ¼ 40 (<1%),
RL ¼ < 40 (<1%), and EL ¼ 43 (<1%);
Adaptive Behavior: VABS-I: ABC ¼ 49
(<1%), DLS ¼ 46 (<1%), and SOC ¼ 64 (1%)
born at 34 weeks, heart defect, sleep apnea,
ear infections, fatigue, fear and anxiety,
obsessive behavior, impulsive behavior,
and difficulties with transitions, attention,
and emotional regulation
Second Ax. Age: 16 yr: ADOS-3 and ADI-R,
met criteria for BEV and COM, but not
for SD; did not meet clinical criteria
(by developmental pediatrician and
psychologist); no ASD Dx; IQ: WASI:
FSIQ ¼ 51 (<1%), VIQ ¼ 55 (<1%),
PIQ ¼ 54 (<1%); Language: OWLS:
TL ¼ 40 (<1%), RL ¼ 40 (<1%),
EL ¼ 40 (<1%)
F1-001
(mother)
46,XX
14q24.3
(77,933,816–77,996,755)
exon 1 (alpha)
none high energy, social difficulties, anxiety,
and auditory and language-processing
difficulties
F2-003
(proband)
46,XY
14q31.1
(79,194,918–79,486,635)
exons 14-17 (alpha)
and 3–7 (beta)
autism (ADI-R
and
ADOS-1)
Age: 3 yr, 5 months; IQ:
Leiter-R IQ ¼ INC; Language: OWLS:
INC; PPVT-4: SS ¼ 67 (<1%); Adaptive
Behavior: VABS-II: ABC ¼ 61 (<1%),
COM ¼ 63 (1%), DLS ¼ 60 (<1%),
SOC ¼ 59 (<1%), and MOT ¼ 72 (3%)
born at 31 weeks, asthma, and juvenile
arthritis
F2-004
(sister)
46,XX
14q31.1
(79,194,918–79,486,635)
exons 14-17 (alpha)
and 3–7 (beta)
autism
(ADI-R and
ADOS-1)
Age: 3 yr, 9 months; IQ:
Leiter-R IQ ¼ 82 (12%); Language:
OWLS: INC; PPVT: INC; Adaptive
Behavior: VABS-II: ABC ¼ 60 (<1%),
COM ¼ 54 (<1%), DLS ¼ 64 (1%),
SOC ¼ 57 (<1%), and MOT ¼ 75 (5%)
born at 31 weeks, asthma, and nonabsent
seizures
F2-001
(father)
46,XY
14q31.1
(79,194,918–79,486,635)
exons 14-17 (alpha)
and 3–7 (beta)
none Alexithymia: TAS-20 ¼ 41
(not alexithymic)
color blind
F3-003
(proband)
46,XY
14q31.1
(~78,503,451–78,839,469)
exons 10-12 (alpha)
and 1 (beta)
autism
(ADI-R)
Age: 13 yr; IQ:
WASI: FSIQ ¼ 71 (3%)
aggression, self harm, obsessive behavior,
suicidal and homicidal thoughts,
delusional and persecutory ideas,
sleep issues, and obesity
F3-001
(father)
46,XY
14q31.1
(~78,503,451–78,839,469)
exons 10-12 (alpha)
and 1 (beta)
BAP
(clinical Dx)
social avoidance, depression, aggression,
alcoholism, obsessive behavior,
compulsive behavior, illiteracy, asthma,
and emphysema
F4-003
(proband)
46,XY
14q31.1
(~78,766,127–79,013,263)
exon 13 (alpha)
and 1–2 (beta)
autism
(clinical Dx,
C-TRF, DSM)
Age: 3 yr, 6 months; IQ:
Leiter-R IQ ¼ INC
aggression, anger, anxiety, temper
tantrums, social avoidance, sucking
and biting of hands and fingers,
sleep-onset disorder, upper-body
hypotonia, thumb-flexion difficulty,
oppositional defiance, previous head
banging, and prior speech delay
Abbreviations are as follows: Dx, diagnosis; Ax, assessment; COM, communication; SD, social deficit; TL, total language; RL, receptive language; EL, expressive
language; DTC, declined to complete; ABC, adaptive behavior composite; DLS, daily living skills; SOC, socialization; INC, incomplete (test was attempted but
subject failed to complete); MOT, motor skills; SS, standardized score; WASI, Wechsler Abbreviated Scale of Intelligence; FSIQ, full scale IQ; VIQ, verbal IQ;
and PIQ, performance IQ. See text for remaining abbreviations.
a NCBI 36 (hg18).
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Figure 2. Extent of Genomic NRXN3 Deletions at Chromosomal Region 14q24.3-q31.1
Deletions are shown in red. CNVs detected in control populations (described in this paper) and from the Database of Genomic Vari-
ants55, 56 are also shown. Genomic coordinates and isoform information are from hg18. Control data are as described in this paper.as ‘‘gifted’’ after being assessed for learning disabilities.
When the boy was between the ages of 9 and 14, there
were concerns of depression. When the proband was 10,
a family stressor might have contributed to suicidal idea-
tion. At 13, he was diagnosed with Asperger syndrome.
He had difficulties with aggression, anger, transitions,
and stimulation, including that from bright lights and
small spaces. His nonverbal cognitive abilities were as-
sessed at age 16 with the Leiter International Performance
Scale-Revised (Leiter-R) measure. He performed above the
expectations for his age compared to his same-aged peers
(92nd percentile). In addition, he completed the Vineland
Adaptive Behavior Scales (VABS) and had age-appropriate
outcomes for communication (39th percentile) and daily
living skills (34th percentile), but his socialization skills
were severely delayed (below the first percentile). Oral
and Written Language Scales (OWLS) testing indicated he
had above average (93rd percentile) receptive language
and listening comprehension, but he declined to complete
measures of expressive language (Oral Expression Scale).
The Autism Diagnostic Interview-Revised (ADI-R), com-
bined with a clinical assessment, was consistent with a
diagnosis of Asperger syndrome. The proband reported
that his mind raced and that he had difficulty sleeping
through the night. He had experienced recurrent episodes
of aggressive outbursts and depression and subsequently
received treatment with risperidone, which was found to
have been ineffective. After he complained of recurrent
headaches, he was diagnosed with bilateral chronic
migraine headaches with episodic visual symptoms that
were most likely due to migraine aura. At 16 years old,
he attended university part-time while maintaining a
part-time job.136 The American Journal of Human Genetics 90, 133–141, January 1F1-003 is one of three children of nonconsanguineous
parents of Irish and English descent. The mother has self-
reported high energy levels, social difficulties, and anxiety,
as well as auditory and language-processing difficulties.
She did not meet criteria for ASD or a BAP upon a clinical
interview assessment. Within the extended maternal
family, there is one third-degree relative with an ASD diag-
nosis, and there are several second- and third-degree rela-
tives with suspected ASD characteristics. The father, who
is apparently healthy, has a brother with Down syndrome
and second- and third-degree relatives with suspected ASD
characteristics.
The proband’s deletion-negative brother (F1-004) has
a normal 46,XY karyotype and a normal FMR-1 repeat.
He was diagnosed with ADHD at age 12; testing with the
Autism Diagnostic Observation Schedule (ADOS: module
4) at age 14 showed that he did not meet formal diagnostic
criteria for ASD. He performed as expected for his age on
the Leiter-R test (63rd percentile). His receptive- and expres-
sive-language skills exceeded expectations for his age
(OWLS, 88th percentile), and his adaptive behavior was
adequate in measures of communication, daily living
skills, and socialization as assessed by VABS.
The proband’s sister (F1-005) was diagnosed with Down
syndrome and possesses a 47,XX,þ21 karyotype and a
normal FMR-1 repeat. A research assessment at age 11 re-
vealed that she was below the first percentile for her age
on the Leiter-R. Her receptive- and expressive-language
skills also fell below the first percentile on the OWLS
assessment. She showed mild to moderate deficits across
her adaptive-behavior profile for her age. She met criteria
for ASD on the ADOS module 2 and the ADI-R behavior
dimension only, but she did not meet clinical criteria3, 2012
when assessed by a developmental pediatrician. Her
behavior was consistent with her trisomy 21 status and
complicated the diagnostic process. At age 16, heightened
anxiety as well as increased obsessive and impulsive behav-
iors prompted a second clinical assessment (Table 1). The
obsessive and repetitive components of her behavior
were the most challenging and interfered with her adap-
tive functioning, but an overall diagnosis of non-ASD
was given.
For family 2, analysis of the male proband’s (F2-003’s)
DNA identified a ~292 kb deletion overlapping several
terminal exons of both the alpha and beta isoforms of
NRXN3 (Figure 2). Microarray analysis of parental DNA
detected the same deletion in the father (F2-002).
Sequencing across the breakpoints showed the deletion
to be 291,717 bp extending from chr14: 79,194,918–
79,486,635 (hg18). Further qPCR validation (Figure S1)
determined the presence of the NRXN3 deletion in the
proband and the father, as well as in the sister (F2-004),
who had an ASD diagnosis, and in the paternal grandfather
(F2-006). Of the other CNVs identified in F2-003, all but
one were previously detected in normal control samples
(Table S5). CNVs identified in F2-004 are listed in Table
S6. Subsequent exome resequencing of F2-001, -002,
-003, -004, and -005 identified five missense variants in
ASD candidate genes9 (Tables S3 and S4), contactin-associ-
ated protein-like 5 (CNTNAP5 MIM [610519]), F-box
protein 40 (FBXO40 [MIM 609107]), and phosphodies-
terase 1C, calmodulin-dependent 70 kDa (PDE1C [MIM
602987]), as well as the neuronally expressed prune
homolog 2 (PRUNE2 [MIM 610691]; Drosophila) and aryl
hydrocarbon receptor nuclear translocator 2 (ARNT2
[MIM 606036]).
Family 2 includes trizygotic triplets; the proband (F2-
003) and an affected sister (F2-004) inherited the NRXN3
deletion from their father, whereas their unaffected
brother (F2-005; Figure 1) did not inherit the deletion
(Table 1). The triplets were conceived naturally by a
23-year-old mother (F2-001) and a 30-year-old father
(F2-002) and were delivered at 31 weeks gestation. The
weights of the affected proband and sister were 3 lbs, 12
oz. and 3 lbs, 4 oz., respectively. Multiple medical interven-
tions were undertaken at birth as a result of the premature
delivery. The proband was born with a right-sided cranial
hemorrhage, and the affected sister was also suspected to
have suffered a cranial hemorrhage at birth. All of the
siblings have continuing difficulty with asthma, the
proband suffers from juvenile arthritis, and the affected
sister has had multiple ear and respiratory infections.
The proband was diagnosed with ASD after a clinical
assessment at 3 years, 5 months of age. During testing
for a research protocol when he was 5 years, 8 months of
age, he met the criteria for an autism diagnosis based on
the ADI-R and the ADOS Module 1. Nonverbal-communi-
cation ability and receptive- and expressive-language skills
could not be assessed because the proband was unable to
complete the intelligence quotient (IQ) (Leiter-R) andThe Americlanguage (OWLS) tests. Testing with the Peabody Picture
Vocabulary Test (PPVT-4) indicated that the proband had
extremely poor receptive-vocabulary skills and adaptive
behavior (VABS-II, below first percentile).
The ASD sister (F2-004) was diagnosed at 3 years,
9 months. As part of a research protocol, she was assessed
at the age of 5 years, 8 months with the ADI-R and the
ADOS Module 1, and she was found to have autism. Her
nonverbal-communication ability was assessed with
Leiter-R and was found to be in the low-average range
(12th percentile) for her age group, whereas her VABS-II
assessment indicated extremely low functioning (below
first percentile). Assessment of her receptive and expressive
language was attempted with the OWLS measure, but it
could not be completed. Receptive-vocabulary testing
(PPVT-4) could not be completed either.
The unaffected brother (F2-005) was assessed at the age
of 4 years, 10 months with a social communication ques-
tionnaire (SCQ), which indicated that he did not have
ASD (total score: 3).
These three children were born to nonconsanguineous
parents of French Canadian descent; neither parent has
an ASD diagnosis. The mother has asthma and was found
not to have a BAP, i.e., she was not alexithymic on the Tor-
onto Alexithymia Scale (TAS-20; total score: 29). The father
is color blind and was also found to be non-BAP (TAS-20;
total score: 41). Clinical information does not exist on
male deletion carrier F2-006.
In a third family, a male proband (F3-003, Figure 1) with
a ~336 kb deletion (chr14: 78,503,451–78,839,469 [hg18])
overlapping exons 10–12 of NRXN3 alpha and exon 1 of
NRXN3 beta was also identified (Figure 2). This individual
originated from a collection of 9,400 patients tested at
Guy’s Hospital, where samples were collected by pediatri-
cians and other health specialists, as well as by genetics
centers both in and outside the region (SE. Thames).48 In
all, 1,368 cases were reported to have ASD.
F3-003 was diagnosed with autism in early childhood,
and clinical testing with an ADI-R at age 13 confirmed
this finding. He displayed aggression, self-harm, obsessive
behaviors, persecutory and delusional ideas, suicidal idea-
tion, and sleep problems. The father, who also carried the
NRXN3 deletion, was assessed by clinical review and was
found to have BAP as well as learning disabilities, depres-
sion, and alcohol-related issues (Table 1).
A fourth family was identified, in which the male
proband (F4-003, Figure 1) had an NRXN3 deletion of
~247kb (chr14: 78,766,127–79,013,263 [hg18]); qPCR con-
firmed that the deletion overlapped exon 13 of NRXN3
alpha and exons 1–2 of NRXN3 beta (Figure 2, Figure S1,
and Table S7). FISH analysis of the proband and parents
determined that the deletion arose de novo (Figure S2).
F4-003 originated from a collection of 13,082 patients
tested at the Mayo Clinic; 1,796 of these patients were
referred to the Mayo Clinic as a result of their having been
diagnosedwith autismorpervasivedevelopmental disorder
(PDD). FMR-1 testing showed a normal repeat number.an Journal of Human Genetics 90, 133–141, January 13, 2012 137
In family 4, the male proband (F4-003, Table 1) was born
at 38 weeks and weighed 8 lbs, 4 oz. The pregnancy was
complicated by insulin-controlled gestational diabetes
and hypertension. He was delivered via a cesarean section
necessitated by maternal hemorrhaging. The neonatal
course was uneventful. During the period from 19 to
24 months of age, the parents first noted that their son
was not easily consoled, developed temper tantrums,
started to bang his head, developed difficulty making eye
contact, and started to develop some stiffness and rigidity.
Between the agesof 2 and3,he couldnot keep to a schedule,
developed extreme reactions to taste and touch, and had
trouble falling asleep. At 2 years, 10 months of age, he
received a clinical diagnosis ofASD, speech languagedelays,
and sleep-onset disorder. At 4 years, 6 months of age, the
Caregiver-Teacher Report Form (C-TRF) for Ages 1.5–5 was
completed; his scores indicated that he had internalizing
andexternalizingproblems.His score on theDSM-Oriented
Scales for Boys was in the clinical range (above the 97th
percentile), indicating pervasive developmental problems.
At 6 years, 10 months of age, he had near-normal speech,
no longer banged his head, and had no oppositional
defiance. Most concerning were his high levels of anxiety
and his temper tantrums in unfamiliar situations. An indi-
vidualized educational plan was put in place for math,
reading, and writing, and he had a one-on-one educational
assistant. Although he was in good general health, he
received occupational therapy for his difficulty with
thumb flexion and his hypotonia of the hands and chest.
To examine whether potential sequence-level muta-
tions, as well as CNVs, in NRXN3 could be associated
with ASD, we sequenced all coding exons and intron-
exon splice sites in NRXN3 in another 350 unrelated ASD
cases. Several inherited missense mutations, but no trun-
cating mutations, were identified in four additional ASD
individuals (Table S8). All of the mutations were inherited
(three were maternal, one was paternal) and occurred
within conserved amino acids, but the effect of these
changes on the function of the resulting protein was not
elucidated. Three of the four missense mutations were
also present in the unaffected siblings.
CNVswithingenes that encode severalneuronal synaptic
proteins have been implicated in ASD and other neurolog-
ical disorders.8,49 The NRXN3 deletions identified here
are very rare events in the general population. There are
reported deletions overlapping exons of NRXN3 alpha in
three female controls and exon 1 of NRXN3 beta in 1 of
15,122examinedcontrols (DNAwasnot available for exper-
imental validation of these computational predictions).
Taken together, the frequency of exonic deletions at the
NRXN3 locus is significantly higher in ASD cases than in
controls (4/4,322 cases versus 4/15,122 controls; Fisher’s
exact test, one-tailed p ¼ 0.039). Furthermore, three of
the four deletions in the ASD cases affect both the alpha
and beta isoforms ofNRXN3, whereas none of the deletions
in the controls do. This difference is also statistically sig-
nificant (3/4,322 ASD cases versus 0/15,122 controls;138 The American Journal of Human Genetics 90, 133–141, January 1Fisher’s exact test, one-tailed p ¼ 0.0055). These findings
parallel what is observed in NRXN1, for which deletions,
while extremely rare, have been reported in a few control
individuals.19,21,24,26 CNVs present in control individuals
might be indicative of reduced penetrance of NXRN3
CNVs (perhaps modified by the nondeleted allele or other
genes), the presence of CNVs within control individuals
in regions where they do not destroy NRXN3 function,
a lack of rigorous testing of the neuropsychiatric phenotype
in the controls, or false-positive calls.50
Our data support the hypothesis that hemizygous
deletions involving NRXN3 might be involved in the
manifestation of an ASD or BAP phenotype. Perhaps
most compelling, the deletion in family 4 arose de novo,
lending strong support for a causative relationship
between the loss of NRXN3 and the development of ASD.
Family 1 carried a deletion that overlapped exon 1 of
NRXN3 alpha; we speculate that this deletionmight predis-
pose affected individuals to a mild ASD or Asperger
syndrome phenotype in the absence of confounding
genomic changes such as trisomy 21, as was observed in
the Down-syndrome-affected sister. Because NRXN3 alpha
is translated from a start site located in exon 2,51,52 it is
possible that the full-length NRXN3 alpha could be
produced despite the deletion. The deletion of exon 1
might decrease transcription of the gene or diminish the
stability of messenger RNA. Interestingly, the same CNV
deletion is present in the mother, who does not have a
formal ASD diagnosis but who self-identified as possessing
several ASD-like characteristics, including anxiety and
social difficulties, as well as auditory and language-process-
ing difficulties. Thus, there might be variable expressivity
of the NRXN3 deletion. It is also possible that there are
additional, currently unidentified, contributing genetic
or environmental factors that could lead to a clinical ASD
phenotype. Although the paternally inherited missense
mutations found in the proband are predicted to be
benign, they might work in conjunction with the mater-
nally inherited NRXN3-alpha deletion to result in the
observed ASD phenotype of the proband.
In contrast, families 2, 3, and 4 carried deletions that
removed multiple exons of both the alpha and beta iso-
forms ofNRXN3. The children carrying these deletions pre-
sented with a more severe form of ASD than that identified
in family 1. This observation, coupled with the absence of
deletions affecting both isoforms of NRXN3 in our
controls, leads us to speculate that the loss of the alpha iso-
form in addition to the loss of the beta isoform might
result in a more severe ASD phenotype. It is perhaps espe-
cially interesting to note that the apparently unaffected
carrier father and paternal grandfather in family 2 carried
the same deletion and missense mutations as the ASD-
affected children, yet they had not been diagnosed with
ASD or BAP. Conversely, the proband of family 3 presented
with autism, whereas the carrier father was diagnosed
with BAP. The complexities of penetrance and variable
expressivity of NRXN3 in ASDmight be partially explained3, 2012
by gene-dosage balance and functional redundancies of
the neurexin gene family.53 Although all three neurexin
genes have similar exonic nucleotide sequences, exon-
intron structure, and patterns of alternative splicing for
mRNAs, NRXN1 and NRXN3 have the greatest sequence
and protein identity. Expression patterns vary between
the neurexin genes and their alpha and beta isoforms.
NRXN3 is expressed throughout the brain, but the other
neurexins show differential locations and intensities of
expression.54
Ultimately, fully understanding genotype and pheno-
type correlations will require knowledge of the diploid
expression patterns of the neurexin genes, other interact-
ing molecules, and perhaps nongenetic factors that might
impede their homeostasis. Our discovery of rare NRXN3
deletions in ASD provides a set of reference cases for the
evaluation of and comparison to other patients, both
enabling the molecular diagnosis of autism and providing
potential new targets for therapeutic intervention.Supplemental Data
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